Krystal Biotech (NASDAQ:KRYS) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Krystal Biotech (NASDAQ:KRYS) posted its earnings results on Monday. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07, Briefing.com reports. The company had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business’s revenue was up 879.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.67) earnings per share.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded up $3.41 on Thursday, hitting $186.50. The company had a trading volume of 73,576 shares, compared to its average volume of 329,350. Krystal Biotech has a 52 week low of $93.95 and a 52 week high of $219.34. The company has a market cap of $5.36 billion, a PE ratio of 103.44 and a beta of 0.82. The business has a 50-day simple moving average of $181.39 and a 200-day simple moving average of $180.25.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 14.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday. Stifel Nicolaus increased their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Evercore ISI boosted their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $197.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).